A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias

Trial Profile

A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs Cobomarsen (Primary) ; Cobomarsen (Primary) ; Cobomarsen (Primary)
  • Indications Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Mycosis fungoides
  • Focus Adverse reactions; First in man
  • Sponsors miRagen Therapeutics
  • Most Recent Events

    • 02 Feb 2018 According to a miRagen Therapeutics media release, interim results from the study were presented at the 10th Annual T-cell Lymphoma Forum.
    • 02 Feb 2018 Interim results published in the miRagen Therapeutics media release.
    • 24 Jan 2018 According to a miRagen Therapeutics media release, interim results from the study will be presented at the 10th Annual T-cell Lymphoma Forum.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top